COMMUNIQUÉS West-GlobeNewswire

Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent
27/09/2019
PITTSBURGH, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin [...]
Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference
27/09/2019
Additional p ositive GEN-009 c linical i mmunogenicity d ata d riven by ATLAS™ to be p resented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 ( [...]
Optinose to Present at the 2019 Cantor Global Healthcare Conference
27/09/2019
YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive [...]
REPEAT: AgraFlora Organics Bolsters European Supply Agreement; Receives C$2,000,000 Cash Infusion
27/09/2019
VANCOUVER, British Columbia, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF ), a growth oriented and diversified [...]
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
27/09/2019
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The [...]
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress
27/09/2019
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]
SmallCap Sentinel: A Hundred Times Better
27/09/2019
ORLANDO, Fla., Sept. 27, 2019 (GLOBE NEWSWIRE) -- The legal cannabis industry- both in the United States and Canada- is evolving. Opportunities abound in this green revolution but the path to market is far from [...]
Trevena to Present at the 2019 Cantor Global Healthcare Conference
27/09/2019
CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous [...]
EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
27/09/2019
WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]
Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors
27/09/2019
BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced the appointment of Michael J [...]
Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
27/09/2019
GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National [...]
AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
27/09/2019
SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation [...]
Press news Biocartis Group: Results of the Special Shareholders’ Meeting held on 27 September 2019
27/09/2019
PRESS RELEASE : REGULATED INFORMATION 27 September 2019, 11:00 CEST Results of the Special Shareholders’ Meeting held on 27 September 2019 Mechelen, Belgium, 27 September 2019 – Biocartis Group NV (the ‘Company’ or ‘ [...]
BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development
27/09/2019
BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative [...]
Philips showcases commitment to improving respiratory care at ERS 2019
27/09/2019
September 27, 2019 Broad portfolio of integrated sleep and respiratory solutions connect data, technology and people across the care continuum Amsterdam, the Netherlands and Madrid, Spain – Royal Philips (NYSE: PHG, AEX [...]
AgraFlora Organics Bolsters European Supply Agreement; Receives C$2,000,000 Cash Infusion
27/09/2019
VANCOUVER, British Columbia, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF ), a growth oriented and diversified [...]
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study
27/09/2019
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Nexstim New System Sales Update
27/09/2019
Press Release, Helsinki, 27 September 2019 at 9.30 am (EET) Nexstim New System Sales Update Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")—the company developing and marketing a unique brain stimulation [...]
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting
27/09/2019
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor regression Expanding [...]

Pages